NEW YORK, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have
commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead
plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links
provided. There is no cost or obligation to you.
India Globalization Capital Inc. (OCTMKTS: IGCC)
Class Period: October 25, 2017 - October 29, 2018
Lead Plaintiff Deadline: January 2, 2019
Join the action: https://www.zlk.com/pslra-1/india-globalization-capital-inc-loss-form?wire=3
About the lawsuit: India Globalization Capital Inc. allegedly made materially false and/or misleading statements during the
class period and/or failed to disclose that: (1) India Globalization’s business model was in a state of change in order to lure
potential blockchain and cannabis investors; (2) India Globalization had overstated the benefits of its relationships with
manufacturers, partners, and distributors in order to inflate the Company’s potential commercial success in the blockchain and
cannabis markets; (3) as a result, the NYSE delisted India Globalization’s shares from their exchange; and (4) consequently,
Defendants’ statements about India Globalization’s business, operations and prospects were materially false and misleading and/or
lacked a reasonable basis at all relevant times. On October 29, 2018 India Globalization announced that NYSE Regulation would
begin the process of delisting the Company and trading would halt immediately.
To learn more about the India Globalization Capital Inc. class action contact jlevi@levikorsinsky.com.
Nektar Therapeutics (NASDAQ: NKTR)
Class Period: November 11, 2017 - October 2, 2018
Lead Plaintiff Deadline: December 31, 2018
Join the action: https://www.zlk.com/pslra-1/nektar-therapeutics-loss-form?wire=3
About the lawsuit: Throughout the class period, Nektar Therapeutics allegedly made materially false and/or misleading statements
and/or failed to disclose that: (1) prior studies which attempted to pegylate IL-2 failed; (2) the extended half-life of the
Company's lead I-O candidate, NKTR-214, was unlikely to result in efficacy and created additional high-dosing safety concerns; (3)
NKTR-214 was less effective than IL-2 alone; (4) the combination of NKTR-214 with nivolumab has yet to demonstrate significant
positive results; and (5) as a result, Nektar’s public statements as set forth above were materially false and misleading at all
relevant times.
To learn more about the Nektar Therapeutics class action contact jlevi@levikorsinsky.com.
Synchrony Financial (NYSE: SYF)
Class Period: October 21, 2016 - November 1, 2018
Lead Plaintiff Deadline: January 2, 2019
Join the action: https://www.zlk.com/pslra-1/synchrony-financial-loss-form?wire=3
The complaint alleges that during the Class Period, Synchrony falsely represented that its consistent and disciplined
underwriting practices had led to a higher quality loan portfolio than those of its competitors. In truth, Synchrony relaxed its
underwriting standards and increasingly offered private-label credit cards to riskier borrowers to sustain growth. The truth about
Synchrony's credit standards began to be revealed on April 28, 2017, when the Company announced disappointing first quarter 2017
earnings driven by poor loan performance. Following this disclosure, the Company represented that it had tightened credit
standards, but falsely characterized those underwriting changes as modest. In fact, the Company had made significant modifications
to its underwriting policies, but concealed that these modifications were damaging its relationships with its retail partners,
including Walmart.
To learn more about the Synchrony Financial class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any
recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys
have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of
dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
